BlackRock to Buy Majority Stake in Humana's CenterWell Clinics for $2.8 Billion

The world's largest asset manager is making one of the biggest bets yet on American senior care. Humana announced on Tuesday that BlackRock will acquire the majority stake in its network of nearly 150 CenterWell Senior Primary Care clinics in a transaction valued at about $2.8 billion — replacing private-equity firm Welsh, Carson, Anderson & Stowe as Humana's partner in one of the country's largest experiments in value-based medicine.

Under the deal, funds and accounts managed by HPS Investment Partners, part of BlackRock, will buy out Welsh Carson's equity in a new joint venture. BlackRock will hold the majority ownership, while Humana's CenterWell division keeps a minority stake and continues to manage and operate every clinic. The transaction, expected to close in the fourth quarter of 2026 pending regulatory approval, is Humana's second strategic deal with BlackRock this year.

What the $2.8 billion actually buys

One important nuance: the $2.8 billion represents the value of Welsh Carson's stake, not cash proceeds flowing to Humana. As Evercore ISI analyst Elizabeth Anderson noted, the main benefit of the transition for Humana is time — more runway to develop the clinic portfolio and raise its profitability, and a later date on which it must decide whether to exercise its buyback option.

The structure is where the deal gets interesting. Starting in 2028, CenterWell will have the option to buy clinics back from the joint venture at its own election. If it has not acquired all of them by the end of 2033, BlackRock can exit through a sale process — with CenterWell holding the right to make the first offer. Crucially, and unlike the previous joint-venture agreements with Welsh Carson, the new deal does not give BlackRock a put option: the right to force Humana to buy out its stake.

Removing that obligation is expected to significantly reduce the liabilities on Humana's balance sheet and lower its cost of capital. Humana described the cheaper funding as a reflection of the CenterWell business's maturity compared with when the legacy joint ventures were formed. The company said the transaction is not expected to have a material impact on its 2026 adjusted earnings guidance — and for investors converting the headline figure, the currency converter translates the $2.8 billion valuation into pounds, euros and rupees at live rates.

What CenterWell does — and why it matters

CenterWell Senior Primary Care is Humana's bet that the future of American healthcare for older adults is not more hospital visits but fewer of them. The clinics practice value-based care: instead of being paid per procedure, the model ties reimbursement to the quality of care and patient health outcomes, sharing financial responsibility for patients' total medical costs. The idea is that intensive, personalised primary care for seniors — managing chronic conditions, coordinating specialists, addressing social needs like food and housing — keeps patients healthier and out of expensive emergency rooms.

The scale is substantial. Humana's Primary Care Organisation — operating under the CenterWell and Conviva brands — runs more than 340 centres across fifteen states and serves over 240,000 members, most of them enrolled in Medicare Advantage plans. The clinics are payer-agnostic, welcoming seniors from many different Medicare Advantage plans as well as some Original Medicare patients, and they use team-based care in which physicians lead multidisciplinary teams covering patients' physical, emotional and social wellbeing.

"We look forward to this new venture with BlackRock as our partner, while our growing network of CenterWell clinics remains dedicated to serving patients with our unique model of senior-focused, value-based care," said Dr Sanjay Shetty, President of CenterWell. He thanked the Welsh Carson team for its "strong partnership and meaningful contribution over the past seven years" — a span during which the private-equity firm poured at least $1.8 billion into the venture, starting in 2020. Six-plus years is precisely the horizon at which private-equity sponsors typically seek an exit, so the timing of the handoff is textbook.

Why BlackRock wants in

For BlackRock, the world's largest investment manager, the deal is a deepening move into healthcare services — an asset class where ageing demographics provide one of the most reliable demand curves in the economy. The United States' over-65 population is growing rapidly, Medicare Advantage enrolment keeps climbing, and value-based primary care has emerged as one of the few care models with evidence of both better outcomes and lower costs.

It is also a vote of confidence in the CenterWell model specifically. HPS Investment Partners, BlackRock's credit-investing arm, is not making a speculative venture bet; it is buying into a scaled, operating clinic network with a proven payer partner and a decade-long runway. Over the next two years, the joint venture is expected to deploy additional capital to fund existing clinic operations, open new clinics and expand through strategic acquisitions — growth money that should accelerate CenterWell's footprint.

This is not BlackRock's first dance with Humana. Earlier this year, Humana agreed to divest its minority interest in Gentiva, a hospice and palliative-care provider, to an investor consortium that includes BlackRock. The two transactions together suggest a deliberate strategy: Humana is reshaping its portfolio around its insurance and primary-care core while bringing in deep-pocketed partners to fund the capital-intensive work of running clinics.

The private-equity-in-healthcare question

The deal lands in the middle of an intensifying national debate about private equity's role in American healthcare. Researchers, journalists and lawmakers have raised concerns about what happens when investor-owned firms buy up medical practices: studies have linked some private-equity acquisitions to higher prices, increased utilisation and, in certain settings, worse outcomes. The CenterWell structure is somewhat different — an insurer-affiliated, value-based model rather than a roll-up of independent practices — but the underlying question is the same: when the owner of your doctor's office is an investment fund, whose interests come first?

Defenders of the model argue that value-based care aligns incentives: because the clinics share financial responsibility for patients' total costs, the profitable move is keeping patients healthy, not ordering more procedures. Critics counter that financial engineering — leverage, fees, aggressive growth targets — can still distort clinical decisions even when the payment model looks virtuous on paper. How BlackRock manages that tension over the next decade, with an exit window opening in 2033, will be watched closely across the industry.

What it means for patients

For the seniors who use CenterWell clinics, the immediate message from Humana is continuity: CenterWell will continue to manage operations at all clinics in the new venture, and the company says patients should experience no disruption in care or decline in quality. The longer-term question is whether BlackRock's growth capital translates into genuinely better access — more clinics, shorter waits, expanded services — or simply a bigger footprint with the same care.

The economics of Medicare Advantage make the answer matter beyond CenterWell's walls. Insurers are paid a fixed amount per member per month by the federal government, so every avoided hospitalisation is margin. If value-based primary care can reliably bend the cost curve while improving outcomes, expect every major insurer to follow Humana's playbook — and every major asset manager to want a piece. The $2.8 billion BlackRock deal may be less a one-off transaction than the opening of a new chapter in who owns American primary care.

Source: STAT News — "BlackRock to buy majority stake in Humana's CenterWell clinics for $2.8 billion" (13 October 2026).

FAQs

What exactly is BlackRock buying for $2.8 billion?

BlackRock, through its HPS Investment Partners arm, is buying Welsh, Carson, Anderson & Stowe's majority equity stake in a new joint venture that will own nearly 150 CenterWell Senior Primary Care clinics. The $2.8 billion is the valuation of that stake — it is not cash going to Humana's shareholders. BlackRock becomes the majority owner; Humana's CenterWell keeps a minority stake and continues running all the clinics day to day.

What is value-based care, and how does CenterWell use it?

In value-based care, providers are paid based on patient health outcomes rather than the number of services they deliver. CenterWell's clinics share financial responsibility for their patients' total medical costs with payers, so the financial incentive is to keep seniors healthy — managing chronic disease, coordinating specialists and addressing social needs — instead of ordering more billable procedures. The model is considered one of the most promising approaches to controlling America's rising healthcare spending while improving quality.

Why is Welsh Carson selling now?

Welsh, Carson, Anderson & Stowe first invested in the CenterWell venture in 2020 and has since put at least $1.8 billion into building the clinic network. More than six years is the classic holding period at which private-equity firms look to exit investments and return capital to their own investors. The firm achieved its objective — scaling CenterWell into the nation's largest senior-focused value-based primary care provider — and is now handing the baton to a longer-horizon owner in BlackRock.

Will this affect the care seniors receive at CenterWell clinics?

Humana says no: CenterWell will continue to manage and operate all clinics in the new joint venture, and the company promises uninterrupted, high-quality care. The practical risk critics watch is subtler — whether new ownership's growth targets and eventual 2033 exit window change investment priorities over time. In the near term, the joint venture's additional capital is earmarked for funding existing operations, opening new clinics and making acquisitions, which should expand access.

Why are big investors buying up primary care clinics?

Demographics and economics. America's over-65 population is surging, Medicare Advantage keeps growing, and primary care — especially value-based models that control downstream hospital costs — offers investors a rare combination: defensive, government-backed revenue and genuine growth. Insurers like Humana want capital partners to fund clinic expansion without straining their own balance sheets; asset managers like BlackRock want exposure to one of the economy's most predictable demand curves. Expect more deals of this kind across the sector.